The Top 5 Biosimilars Articles for the Week of September 23

September 27, 2019

The Center for Biosimilars® recaps the top stories for the week of September 23, 2019.

Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of September 23, 2019.

Number 5: Generium has received approval for the first biosimilar dornase alfa, which treats cystic fibrosis, in Russia.

Number 4: A newly published paper concludes that, as experience and analytical capabilities mature, there will be a reduced requirement for clinical data in biosimilar development.

Number 3: Two biosimilar bills, both with bipartisan sponsors, were unveiled last week.

Number 2: The Committee for Medicinal Products for Human Use issued a positive opinion for Celltrion’s subcutaneously administered biosimilar infliximab for the treatment of rheumatoid arthritis.

Number 1: The FDA has released a new suite of resources to educate patients about biosimilars.

Finally, last week, our e-newsletter asked whether you think that the 2020 launch of authorized generics of 2 of Novo Nordisk’s insulin products will help patients afford their medication.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.